

Corneal Endothelial Dystrophy Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

Corneal Endothelial Dystrophy Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 25, 2025

[/EINPresswire.com/](https://EINPresswire.com/) -- Updated 2025
Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



The Business
Research Company

The Business Research Company

The [corneal endothelial dystrophy global market](#) report reveals a dynamic and growing market that is predicted to surge from a worth of \$170.96 billion in 2024 to \$185.38 billion in 2025. This

“

The corneal endothelial dystrophy market size is expected to see strong growth in the next few years. It will grow to \$252.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%.”

*The Business Research
Company*

rapid market expansion represents a compound annual growth rate CAGR of 8.4% and can be credited to a variety of contributory factors such as escalating healthcare expenditures, a rise in the prevalence of endothelial corneal dystrophy, a burgeoning aging population, increasing pervasiveness of eye diseases, and surge in prevalence of corneal disorders.

What will be the future growth of the corneal endothelial dystrophy market?

The promising future of the corneal endothelial dystrophy market is confirmed with expectations of strong growth in the subsequent years. The market is poised to expand to

\$252.88 billion by 2029 at a compound annual growth rate CAGR of 8.1%. The escalation during the forecast period is partly attributable to a rise in corneal blindness in emerging economies, accentuated awareness about eye care, an increased demand for corneal transplantation, boosted healthcare infrastructure, and an upswing in the prevalence of chronic disorders. Advanced therapeutic developments including advancements in regenerative therapies, medical technology, diagnostic techniques, ophthalmic lasers, and other technologies are expected to

represent significant drivers of this market growth into the foreseeable future.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample_request?id=21158&type=smp

What are the key drivers pushing the [corneal endothelial dystrophy market forward](#)?

A key market driver promoting growth is the growing demand for corneal transplantation. As a surgical procedure where a damaged or diseased cornea is substituted with a healthy donor cornea to restore vision and augment eye health, corneal transplants are becoming increasingly popular. Rising prevalence of corneal diseases coupled with advancements in surgical techniques and elevated organ donation rates contribute to this growth. As an example, in 2023, the Eye Bank Association of America reported an increase in keratoplasty procedures a form of corneal transplantation of 2.7%, from 49,597 in 2022 to 50,925 in 2023.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/corneal-endothelial-dystrophy-global-market-report>

Who are the key industry players in the corneal endothelial dystrophy market?

The corneal endothelial dystrophy market is shaped by offerings from key industry players including F. Hoffmann-La Roche AG, Abbvie Allergan plc, Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, and Emmecell S.R.L.

What are some of the emerging trends in the corneal endothelial dystrophy market?

In a bid to address existing medical needs and provide minimally invasive treatment options that improve patient outcomes, these key players are committed to the development of innovative treatments such as allogeneic cell therapy. For instance, in September 2024, Aurion Biotech Inc. launched Vyznova neltependocel in Japan for the treatment of bullous keratopathy, a corneal endothelial disease. This cell therapy is paving new ground by offering a less invasive alternative to corneal transplants, essentially harnessing lab-grown corneal endothelial cells to address the shortage of donor corneas.

How is the [corneal endothelial dystrophy market segmented](#)?

The corneal endothelial dystrophy market can be segmented by:

1 Treatment: Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps

2 Disease Type: Congenital Hereditary Endothelial Dystrophy 1, Congenital Hereditary Endothelial Dystrophy 2, Posterior Polymorphous Corneal Dystrophy, Fuchs Endothelial Corneal Dystrophy

3 Diagnosis: Cornea Examination And Grading, Corneal Tomography, Corneal Pachymetry,

Corneal Cell Count

4 End-User: Hospitals, Clinics, Other End Users

Which region dominates the corneal endothelial dystrophy market?

Regionally, North America represented the largest market share in 2024, with Asia-Pacific anticipated to be the fastest-growing region in the forthcoming years.

Browse For More Similar Reports-

Corneal Implants Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/corneal-implants-global-market-report>

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report>

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report>

About The Business Research Company:

The Business Research Company boasts a repository of over 15000+ reports spanning 27 industries and 60+ geographies. It prides itself on comprehensive, data-rich research and insights. Armed with 1.5 million datasets, in-depth secondary research, and unique insights from industry leaders, it provides valuable data that helps you to stay ahead in the game.

Get in touch:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us: info@tbrc.info

Stay connected:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/796910723>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.